HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Dr Tanios Bekaii-Saab

Dr. Tanios Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts. Dr. Bekaii-Saab is a Professor of Medicine at the Mayo Clinic College of Medicine and Science, Leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, Medical Director of the Cancer Clinical Research Office, and Vice Chair and Section Chief for Medical Oncology for the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona.

 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551